Diabetes raises pancreatic cancer risk - study
Posted on: Tuesday, 2 August 2005, 18:19 CDT
WASHINGTON (Reuters) - Middle-aged and older Americans who are newly diagnosed with diabetes also appear to have a higher risk of deadly pancreatic cancer, according to a study published on Tuesday.
For three years after their diagnosis with diabetes, patients have eight times the risk of developing pancreatic cancer, the study at the Mayo Clinic Cancer Center found.
Diabetes itself may be an early symptom of the hard-to-treat cancer, the researchers said.
"Pancreatic cancer is difficult to detect until it is in an advanced stage, leaving little hope for patients," said Dr. Suresh Chari, who led the study.
"This study is important, because it leads us closer to finding indicators that will allow earlier detection and treatment."
Pancreatic cancer kills virtually all of the 32,000 people who are diagnosed with the disease in the United States, making it the fourth leading cause of cancer death. This is in part because it shows few symptoms before it becomes advanced.
Writing in the journal Gastroenterology, Chari and colleagues said they studied 2,122 patients from Rochester, Minnesota, aged 50 and older who were diagnosed with diabetes between 1950 and 1995.
Pancreatic cancer is uncommon -- 18 of the patients were diagnosed with the cancer within three years.
Chari's team compared this rate with the rate expected for people of similar age and sex without diabetes. The group with newly diagnosed diabetes had eight times the expected rate.
Type-2 diabetes is diagnosed when the body no longer responds properly to insulin, but, as with type-1 diabetes, can be caused by the destruction of cells in the pancreas.
"More research is needed to determine if using increased sugar levels as an indicator of pancreatic cancer is feasible," Chari said in a statement.
"Our goal now is to identify a marker in the blood that will enable us to distinguish diabetes associated with pancreatic cancer from the far more common type-2 diabetes."
Source: REUTERS
Related Articles
- Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol(R) (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes
- Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study
- Low Blood Sugar Events Increase Dementia Risk in Elderly Patients With Type 2 Diabetes, Kaiser Permanente Study Finds
- Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients With Type 1 and Type 2 Diabetes
- Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
- MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who Are Overweight
- Published Study Finds That More Than One-Third of Patients With Type 2 Diabetes Also Suffer From Obstructive Sleep Apnea
- New Study Shows an Innovative Mealtime Insulin Dosing Algorithm May Provide a Safe and Effective Alternative to Carbohydrate Counting for Patients With Type 2 Diabetes
- Generex Biotechnology Announces Commencement of a New European Clinical Study of Oral-Lyn(TM) in Patients With Type-1 Diabetes
- New Analysis in Patients With Type 2 Diabetes From Trial With VYTORIN-TM- -Ezetimibe/Simvastatin- Presented at ADA; Consistent With Overall Study Which Showed Superior LDL Cholesterol Reduction With VYTORIN Versus Lipitor
User Comments (0)


RSS Feeds